Selective JAK Inhibition in RA vs PV - Top-Institutions - MDSpire

Selective JAK Inhibition in RA vs PV

Tofacitinib induced remission of rheumatoid arthritis but spared JAK2-driven polycythemia vera in a single case report.

  • By

  • Julia Cipriano

  • February 13, 2026

  • 3 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Hematology
    • Translational Medicine

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Rheumatology
    • Hematology
    • Immunology

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Rheumatology
    • Hematology
    • Molecular Medicine

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Rheumatology
    • Hematology
    • Clinical Pharmacology

Original Source(s)

Selective JAK Inhibition in RA vs PV

  • by Julia Cipriano

  • February 13, 2026

Related Content

Leukemia Case Prompts Broader Review

Researchers assess hematologic malignancies temporally associated with mRNA COVID-19 vaccination.

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.